Syros Pharmaceuticals Inc expected to post a loss of $4.01 a share - Earnings Preview

Syros Pharmaceuticals

01/11/2022 18:27

* Syros Pharmaceuticals Inc  SYRS.OQ   SYRS.O  is expected
to show
a fall in quarterly revenue when it reports  results on November
3 (estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 8.3% decrease in revenue to $5.225 million from $5.7 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Syros
Pharmaceuticals Inc
is for a loss of $4.01 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $40​, above​ its last closing price
of $5.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -3.92       -4.08      -5.40     Missed  -32.4
 Mar. 31 2022  -4.64       -4.70      -4.00     Beat    14.9
 Dec. 31 2021  -4.50       -4.66      -3.80     Beat    18.4​
 Sep. 30 2021  -4.41       -4.40      -4.10     Beat    6.8
 ​​Jun.        -3.70       -3.72      -3.60     Beat    3.3
 30 2021                                                
 Mar. 31 2021  -4.57       -4.65      -2.30     Beat    50.5​
 Dec. 31 2020  -5.90       -4.99      -6.20     Missed  -24.2
 Sep. 30 2020  -3.84       -3.84      -4.30     Missed  -11.9
 This summary was machine generated November 1 at 18:26 GMT.  All
figures in US dollars  unless otherwise stated